Original articleManagement of Ocular Hypertension: A Cost-effectiveness Approach From the Ocular Hypertension Treatment Study
Section snippets
Methods
We constructed a Markov decision model to compare the cost and effectiveness of treating ocular hypertension over a lifetime. Parameters in the model included estimates of the risk of POAG among those patients for whom pressure lowering medication were prescribed and those patients for whom they were not, the probability of progression of POAG to unilateral blindness, the probability of bilateral blindness among patients with unilateral blindness, and estimates of the impact of POAG and
Results
The cost-effectiveness of treatment of ocular hypertension at each treatment threshold is shown in Figure 2. Each point represents the combination of expected lifetime cost (on the vertical axis) and QALYs gained (on the horizontal axis) that are associated with each treatment threshold: “Treat no one,” “Treat ≥5%,” “Treat ≥2%,” and “Treat everyone.” In Table 3, the thresholds are ranked according to the expected lifetime cost of treatment/person, with “Treat no one” the least expensive and
Discussion
A clinical management strategy that targets a 20% reduction in IOP in people with ocular hypertension has been shown to delay or prevent the onset of glaucoma.8 However, many clinicians continue to maintain that treatment of ocular hypertension is not warranted.9, 37 We have shown that the treatment of people with the highest risk (that is, an annual risk of ≥5% or a five-year risk in excess of 25%; at least 10% of people with IOP of ≥24 mm Hg in the OHTS sample) is highly cost-effective at a
Steven M. Kymes, PhD, is a Research Assistant Professor in the Department of Ophthalmology and Visual Sciences at Washington University in St Louis, Missouri. Dr Kymes is an Assistant Director of the Vision Research Coordinating Center. Before entering academic life, Dr Kymes held various management and marketing positions with health care and managed care organizations. Dr Kymes’ research interests concern cost-effectiveness of medical treatment and testing, assessment of health-related
References (53)
- et al.
Prevalence of open-angle glaucoma and ocular hypertension in LatinosThe Los Angeles Latino Eye Study
Ophthalmology
(2004) - et al.
The prevalence of primary open-angle glaucoma in a population-based study in The NetherlandsThe Rotterdam Study
Ophthalmology
(1994) - et al.
Cost-utility analysis of cataract surgery in the second eye
Ophthalmology
(2003) - et al.
Principles of good practice for decision analytic modeling in health-care evaluation: report of the ISPOR Task Force on good research practices: modeling studies
Value Health
(2003) - et al.
Risk factors for incident nuclear opacities
Ophthalmology
(2002) - et al.
Five-year incidence of open-angle glaucoma
Ophthalmology
(2002) - et al.
Glaucoma and survival
Ophthalmology
(2003) Glaucoma and mortalitya connection
Ophthalmology
(2003)- et al.
The probability of blindness from open-angle glaucoma
Ophthalmology
(1998) - Lighthouse International. New approach to assessing glaucoma risk may help physicians decide who needs treatment:...
Vision problems in the United States
Racial differences in the cause-specific prevalence of blindness in east Baltimore
N Engl J Med
The epidemiology of open-angle glaucoma
Am J Epidemiol
The Ocular Hypertension Treatment Studybaseline factors that predict the onset of primary open-angle glaucoma
Arch Ophthalmol
Practice policies and guidelinesWhere do they come from?
The Ocular Hypertension Treatment Studya randomized trial determines that topical hypotensive medication delays or prevents the onset of primary open-angle glaucoma
Arch Ophthalmol
The Ocular Hypertension Treatment StudyIntraocular pressure lowering prevents the development of glaucoma, but does that mean we should treat before the onset of disease?
Arch Ophthalmol
Glaucoma patients’ assessment of their visual function and quality of life
Trans Am Ophthalmol Soc
Visual function and quality of life among persons with glaucoma
Arch Ophthalmol
The Ocular Hypertension Treatment Studydesign and baseline description of the participants
Arch Ophthalmol
A multi-center, retrospective pilot study of resource utilization and costs associated with severity of disease in glaucoma
Arch Ophthalmol
Clinical decisions in glaucoma
The Markov process in medical prognosis
Med Decis Making
What is the cost of blindness?
Br J Ophthalmol
Cited by (80)
Detection and measurement of clinically meaningful visual field progression in clinical trials for glaucoma
2017, Progress in Retinal and Eye ResearchPrimary Open-Angle Glaucoma
2016, OphthalmologyPrimary Open-Angle Glaucoma Suspect
2016, OphthalmologyEconomics of Glaucoma Care
2015, Glaucoma: Second EditionManagement of Ocular Hypertension and Primary Open-Angle Glaucoma
2015, Glaucoma: Second EditionMedical Management of Glaucoma: Cost-Effectiveness
2015, Glaucoma: Second Edition
Steven M. Kymes, PhD, is a Research Assistant Professor in the Department of Ophthalmology and Visual Sciences at Washington University in St Louis, Missouri. Dr Kymes is an Assistant Director of the Vision Research Coordinating Center. Before entering academic life, Dr Kymes held various management and marketing positions with health care and managed care organizations. Dr Kymes’ research interests concern cost-effectiveness of medical treatment and testing, assessment of health-related quality of life, and the relationship between insurance plan design and health outcomes.
Mae O. Gordon, PhD, is a Professor in the Department of Ophthalmology and Visual Sciences at Washington University in St Louis, Missouri. Dr Gordon is the Director of the Vision Research Coordinating Center at Washington University and is Co-Chairman of the Ocular Hypertension Treatment Study. Among her areas of research are clinical trial design, assessment of quality of life, and persistency in treatment of glaucoma.
Supplemental Material available at AJO.com.
Supported by Awards to the Washington University School of Medicine Department of Ophthalmology and Visual Sciences from the National Eye Institute, the National Center on Minority Health and Health Disparities, National Institutes of Health (grants EY09341 and EY09307), and unrestricted grants from Merck Research Laboratories and Pfizer, Inc; and by Awards to the Washington University Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness, Inc, and the National Institutes of Health (P30 EY 02687) Core grant.
For a complete list of OHTS investigators, please see the OHTS website at https://vrcc.wustl.edu